^（211）At标记单克隆抗体3H11及其对人胃癌细胞DNA和RNA合成的影响  

^(211)At labelling of 3H11 McAb and its effect on DNA and RNA synthesis in gastric cancer cell

作　　者：刘宁[1] 金建南[1] 张叔渊[1] 王娟[1] 罗林[1] 王方元[1] 罗德元[1] 周懋伦[1] 万文徽[2] 董志伟[2] 

机构地区：[1]四川大学原子核科学技术研究所 [2]北京市肿瘤防治研究所

出　　处：《核技术》1994年第11期697-701,共5页Nuclear Techniques

基　　金：高等学校博士点基金资助项目

摘　　要：采用间接标记方法，先合成对砹苯甲酸中间体，再与抗胃癌单抗３Ｈ１１偶联制得２１１Ａｔ－３Ｈ１１。２１１Ａｔ－３Ｈ１１的放化产率不低于２１１Ａｔ初始活度的３０％，其放射性比度可达１１１ＧＢｑ／ｇＭｃＡｂ。标记后２１１Ａｔ－３Ｈ１１的免疫活性与未标记的３Ｈ１１ＭｃＡｈ一致。核素前体参人法研究表明，２１１Ａｔ－３Ｈ１１对人胃癌细胞ＤＮＡ、ＲＮＡ合成的抑制效应强于Ｎａ２１１Ａｔ，尤其抑制ＲＮＡ合成，其作用呈量效关系。２１１Ａｔ－３Ｈ１１作用解除后，ＤＮＡ合成可逐渐恢复，提示２１１Ａｔ－３Ｈ１１为干扰代谢型药物。At-3H11 McAb was prepared with an indirect labelling method which 211At was coupled to 3H11 McAb via paraastato-benzoic acid intermediate. At least 30% of the added 211At was found in the product, the specific activity of which was up to 111GBq/g McAb. Its radio￣unity was verified by ELISA method. Nuclide precursorincorporation techniques revealed that 211At-McAb inhibited the incorporation of 3H-TdR and 3H-UR into gastric cancer, especially the latter. The inhibition effect was dependent on the concentration of 211At-McAb and was stronger than that of Na211At.

关 键 词：单克隆抗体 胃癌 间接标记法 DNA 砹211 

分 类 号：R735.2[医药卫生—肿瘤] R730.55[医药卫生—临床医学]